228 related articles for article (PubMed ID: 36379199)
21. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
[TBL] [Abstract][Full Text] [Related]
22. Clinical efficacy of PARP inhibitors in breast cancer.
Pandya K; Scher A; Omene C; Ganesan S; Kumar S; Ohri N; Potdevin L; Haffty B; Toppmeyer DL; George MA
Breast Cancer Res Treat; 2023 Jul; 200(1):15-22. PubMed ID: 37129747
[TBL] [Abstract][Full Text] [Related]
23. Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer: Overcoming Challenges in Genetic Testing and Clinical Considerations When Using Talazoparib.
Brugioni E; Cathcart-Rake E; Metsker J; Gustafson E; Douglass L; Pluard TJ
Clin Breast Cancer; 2023 Jul; 23(5):469-477. PubMed ID: 37246120
[TBL] [Abstract][Full Text] [Related]
24. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.
Senkus E; Delaloge S; Domchek SM; Conte P; Im SA; Xu B; Armstrong A; Masuda N; Fielding A; Robson M; Tung N
Int J Cancer; 2023 Aug; 153(4):803-814. PubMed ID: 36971103
[TBL] [Abstract][Full Text] [Related]
25. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline
Desai NV; Tan AR
JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718
[TBL] [Abstract][Full Text] [Related]
26. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
Armstrong AC; Clay V
Future Oncol; 2019 Jul; 15(20):2327-2335. PubMed ID: 31304797
[TBL] [Abstract][Full Text] [Related]
27. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
[TBL] [Abstract][Full Text] [Related]
29. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J
Lancet; 2010 Jul; 376(9737):235-44. PubMed ID: 20609467
[TBL] [Abstract][Full Text] [Related]
30. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline
Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke EM; Mina LA; Balmaña J; Fasching PA; Hurvitz SA; Wardley AM; Chappey C; Hannah AL; Robson ME;
Clin Cancer Res; 2019 May; 25(9):2717-2724. PubMed ID: 30563931
[TBL] [Abstract][Full Text] [Related]
31. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.
Blum JL; Laird AD; Litton JK; Rugo HS; Ettl J; Hurvitz SA; Martin M; Roché HH; Lee KH; Goodwin A; Chen Y; Lanzalone S; Chelliserry J; Czibere A; Hopkins JF; Albacker LA; Mina LA
Clin Cancer Res; 2022 Apr; 28(7):1383-1390. PubMed ID: 35091441
[TBL] [Abstract][Full Text] [Related]
32. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
33. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
34. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Ettl J; Quek RGW; Lee KH; Rugo HS; Hurvitz S; Gonçalves A; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Markova D; Bhattacharyya H; Hannah AL; Eiermann W; Blum JL; Litton JK
Ann Oncol; 2018 Sep; 29(9):1939-1947. PubMed ID: 30124753
[TBL] [Abstract][Full Text] [Related]
35. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
Im SA; Xu B; Li W; Robson M; Ouyang Q; Yeh DC; Iwata H; Park YH; Sohn JH; Tseng LM; Goessl C; Wu W; Masuda N
Sci Rep; 2020 May; 10(1):8753. PubMed ID: 32472001
[TBL] [Abstract][Full Text] [Related]
36. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
37. Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
Garber HR; Litton JK
Curr Opin Oncol; 2019 May; 31(3):247-255. PubMed ID: 30789866
[TBL] [Abstract][Full Text] [Related]
38. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
39. PARP inhibitor treatment of advanced breast cancer beyond the
Yan F; Jiang Q; He M; Shen P
Future Oncol; 2021 Jun; 17(18):2381-2393. PubMed ID: 33784822
[TBL] [Abstract][Full Text] [Related]
40. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Robson M; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Delaloge S; Li W; Tung N; Armstrong A; Wu W; Goessl C; Runswick S; Conte P
N Engl J Med; 2017 Aug; 377(6):523-533. PubMed ID: 28578601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
